Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study

BACKGROUND: Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel (oPAC) may be more convenient, less resource-intensive, and more tolerable than its intravenous...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Ming-Shen, Chao, Ta-Chung, Chiu, Chang-Fang, Lu, Yen-Shen, Shiah, Her-Shyong, Jackson, Christopher G. C. A., Hung, Noelyn, Zhi, Jianguo, Cutler, David L., Kwan, Rudolf, Kramer, Douglas, Chan, Wing-Kai, Qin, Albert, Tseng, Kuan-Chiao, Hung, Cheung Tak, Chao, Tsu-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363869/
https://www.ncbi.nlm.nih.gov/pubmed/37492633
http://dx.doi.org/10.1177/17588359231183680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363869/
https://www.ncbi.nlm.nih.gov/pubmed/37492633
http://dx.doi.org/10.1177/17588359231183680

Ejemplares similares